Skip to contentT
Travere Therapeutics, Inc.
T
TVTXTravere Therapeutics, Inc. Q3 2018 · 10-Q
Revenue$40.71M$40.71M+0.9% vs Q3 2017 Net Income-$54.52M-$54.52MN/M vs Q3 2017 EPS Diluted-$1.34-$1.34N/M vs Q3 2017 Operating Income-$35,583,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Travere Therapeutics, Inc. · CIK 1438533 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$4,025,000N/M Margins · derivedOperating margin-87.4%−61.1 pt vs Q3 2017
Net margin-133.9%−89.8 pt vs Q3 2017
ended Sep 30, 2018 · filed Nov 1, 2018 · 32 d after period end